FDA Brief

Warning letters Drugs

FDA warning letter to

Discover Health, LLC d/b/a Discover CBD and Strain Snobs

High riskIssued Nov 16, 2023Posted Nov 21, 2023Center for Drug Evaluation and Research | CDER

FDA warns Discover Health over unapproved CBD, CBG, HHC, and Delta-8 THC drugs, unsafe CBD/Delta-8 foods, and unapproved animal drugs.

What happened

FDA reviewed the company’s websites at discovercbd.com and activecbdoil.com and its Instagram from June to August 2023. FDA found products containing CBD, CBG, HHC, and Delta-8 THC marketed with claims to treat diseases such as cancer, epilepsy, PTSD, and opioid addiction, plus CBD/Delta-8 THC in foods and CBD in pet products.

What FDA found

  1. The company markets CBD, CBG, HHC, and Delta-8 THC products with claims to treat cancer, epilepsy, PTSD, diabetes, glaucoma, and opioid addiction, making them unapproved new drugs.

    FD&C Act sections 505(a) and 301(d), 21 U.S.C. 355(a) and 331(d)
  2. The drug products’ labeling lacks adequate directions for use, so they are misbranded (labeling violates the law).

    FD&C Act section 502(f)(1), 21 U.S.C. 352(f)(1); 21 CFR 201.5
  3. CBD added to coffee, gummies, and water is an unsafe food additive, making those foods adulterated (unsafe under the law).

    FD&C Act sections 402(a)(2)(C)(i) and 409, 21 U.S.C. 342(a)(2)(C)(i) and 348(a)
  4. Delta-8 THC added to plant-based gummies is an unsafe food additive, making the gummies adulterated.

    FD&C Act sections 402(a)(2)(C)(i) and 409, 21 U.S.C. 342(a)(2)(C)(i) and 348(a)
  5. CBD pet treats and tinctures are unapproved new animal drugs and are adulterated.

    FD&C Act sections 512(a) and 501(a)(5), 21 U.S.C. 360b(a) and 351(a)(5)
  6. The CBD pet products also contain an unsafe food additive and are prohibited from interstate commerce.

    FD&C Act sections 402(a)(2)(C)(i) and 301(ll), 21 U.S.C. 342(a)(2)(C)(i) and 331(ll)

What FDA wants

FDA advises the company that the products may not be introduced into interstate commerce as sold and points it to FDA’s cannabis-product information; no response deadline is stated in the provided letter.

Who should pay attention

  • CBD and hemp brands selling foods, drugs, or pet products
  • retailers and distributors of Delta-8 THC products
  • companies making disease-treatment claims for CBD

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natuzem

    FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.

    High risk
  2. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  3. Calibrate IV Hydration

    FDA told Calibrate IV Hydration its umbilical cord and exosome IV products are unapproved drugs and unlicensed biologics.

    High risk
  4. Best Chinese Medicines LLC

    FDA warned Best Chinese Medicines LLC that five herbal products sold online are unapproved new drugs because their labeling claims to treat diseases.

    High risk